FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	S IN BENEFICIAL	L OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Luthringer Remy</u>				2. Issuer Name and Ticker or Trading Symbol Minerva Neurosciences, Inc. [NERV]						(Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) (First) (Middle) C/O MINERVA NEUROSCIENCES, INC. 1601 TRAPELO ROAD, SUITE 284					3. Date of Earliest Transaction (Month/Day/Year) 12/04/2015							_	give title President	Other (below)		
(Street) WALTHAM MA 02451 (City) (State) (Zip)				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)					6. In Line						
1. Title of Security (Instr. 3) 2. Transa Date				ransactio			Code (Instr.			ed (A) or	5. Amoun	Form (D) o	Ownership orm: Direct O) or Indirect) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
Table II - Derivat				ivative	tive Securities Acqu			Code V			(A) or (D) Price		Transaction(s) (Instr. 3 and 4)			(Instr. 4)
								, options	•			•				
1. Title of Derivative Security (Instr. 3)	or Exercise (Month/Day/Year) if any		Execution Date,	Code (Instr.		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		C	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)		Date Exercisable	Expiration Date		Title	Amount or Number of Shares		(Instr. 4)		
Stock Option (right to buy)	\$4.71 ⁽¹⁾	12/04/2015		A		320,000		(2)	12/03/20	25	Common Stock	320,000	\$0.00	320,000	D	

Explanation of Responses:

- 1. The exercise price is the closing price of the Issuer's common stock on December 4, 2015.
- 2. This option shall vest as follows: 25% on December 4, 2016; and then in quarterly installments over 3 years thereafter.

Remarks:

/s/ Mark Levine, Attorney-in-

Fact

** Signature of Reporting Person

Date

12/08/2015

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.